Clinical Trial Update: Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sitravatinib plus tislelizumab vs controls in hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sitravatinib (sitravatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: WITHDRAWN